ERS/EAACI statement on severe exacerbations in asthma in adults: facts, priorities and key research questions

Arnaud Bourdin1, Leif Bjermer2, Christopher Brightling3, Guy G. Brusselle4, Pascal Chanez5, Kian Fan Chung6, Adnan Custovic7, Zuzana Diamant8,9, Sarah Diver10, Ratko Djukanovic11, Dominique Hamerlijnck12, Ildikó Horváth13, Sebastian L. Johnston14, Frank Kanniess15, Nikos Papadopoulos16,17, Alberto Papi18, Richard J. Russell19, Dermot Ryan20,21, Konstantinos Samitas22, Thomy Tonia23, Eleftherios Zervas24 and Mina Gaga24

Affiliations: 1Université de Montpellier, CHU Montpellier, PhyMedExp, INSERM, CNRS, Montpellier, France. 2Dept of Respiratory Medicine and Allergy, Lung and Allergy research Unit, Lund, Sweden. 3Dept of Infection, Immunity and Inflammation, Institute for Lung Health, NIHR BRC Respiratory Medicine, University of Leicester, Leicester, UK. 4Dept of Respiratory Diseases, Ghent University Hospital, Ghent, Belgium. 5University of Marseille, Marseille, France. 6National Heart and Lung Institute, Imperial College, London, UK. 7Dept of Paediatrics, Imperial College London, London, UK. 8Dept of Respiratory Medicine and Allergology, Skane University Hospital, Lund, Sweden. 9Respiratory and Allergy Research, QPS Netherlands, The Netherlands. 10Dept of Respiratory Sciences, College of Life Sciences, Respiratory Biomedical Research Unit, Glenfield Hospital, Leicester, UK. 11University Hospital Southampton NHS Foundation Trust, Southampton, UK. 12National Koranyi Institute for Pulmonology, and Dept of Public Health, Semmelweis University, Budapest, Hungary. 13Dept of Respiratory Medicine, Imperial College London, London, UK. 14Reinfeld, Germany. 15Division of Infection, Immunity and Respiratory Medicine, University of Manchester, Manchester, UK. 16Allergy Dept, 2nd Pediatric Clinic, University of Athens, Athens, Greece. 17Respiratory Medicine, University of Ferrara, Ferrara, Italy. 18Institute for Lung Health, NIHR Leicester Biomedical Research Centre, Dept of Infection, Immunity and Inflammation, University of Leicester, Leicester, UK. 19Allergy and Respiratory Research Group, Centre for Population Health Sciences, University of Edinburgh, Edinburgh, UK. 20Woodbrooke Medical Centre, Loughborough, UK. 217th Resp. Med. Med. Dept and Asthma Centre, Athens Chest Hospital, Athens, Greece. 22Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland. 237th Respiratory Medicine Dept, Athens Chest Hospital, Athens, Greece.

Correspondence: M. Gaga, Athens Chest Hospital Sotiria, 7th Respiratory Medicine Dept, 152 Mesogion Ave, Athens, 15452, Greece. Email: minagaga@yahoo.com

ABSTRACT Despite the use of effective medications to control asthma, severe exacerbations in asthma are still a major health risk and require urgent action on the part of the patient and physician to prevent serious outcomes such as hospitalisation or death. Moreover, severe exacerbations are associated with substantial healthcare costs and psychological burden, including anxiety and fear for patients and their families. The European Academy of Allergy and Clinical Immunology (EAACI) and the European Respiratory Society (ERS) set up a task force to search for a clear definition of severe exacerbations, and to also define research questions and priorities. The statement includes comments from patients who were members of the task force.